High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab

被引：0
|
作者：
Kjeldsen, Julie W. [1 ]
Lorentzen, Cathrine L. [1 ]
Martinenaite, Evelina [1 ,2 ]
Ellebaek, Eva [1 ]
Donia, Marco [1 ]
Ehrnrooth, Eva [3 ]
Andersen, Mads H. [1 ,2 ]
Svane, Inge Marie [1 ]
机构：
[1] Herlev Hosp, Dept Oncol, Natl Ctr Canc Immune Therapy CCIT DK, Herlev, Denmark
[2] Herlev Hosp, Dept Oncol, IO Biotech ApS, Herlev, Denmark
[3] IO Biotech ApS, Copenhagen, Denmark
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT535
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress
    Kjeldsen, J. W.
    Andersen, M. H.
    Svane, I-M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [2] Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
    Svane, I-M.
    Kjeldsen, J. W.
    Lorentzen, C. L.
    Martinenaite, E.
    Andersen, M. H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1176 - S1176
  • [3] Long-term follow-up of anti-PD-1 naive patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
    Lorentzen, Cathrine Lund
    Kjeldsen, Julie Westerlin
    Ehrnrooth, Eva
    Andersen, Mads Hald
    Svane, Inge Marie
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (05)
  • [4] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
    Kjeldsen, Julie Westerlin
    Lorentzen, Cathrine Lund
    Martinenaite, Evelina
    Ellebaek, Eva
    Donia, Marco
    Holmstroem, Rikke Boedker
    Klausen, Tobias Wirenfeldt
    Madsen, Cecilie Oelvang
    Ahmed, Shamaila Munir
    Weis-Banke, Stine Emilie
    Holmstrom, Morten Orebo
    Hendel, Helle Westergren
    Ehrnrooth, Eva
    Zocca, Mai-Britt
    Pedersen, Ayako Wakatsuki
    Andersen, Mads Hald
    Svane, Inge Marie
    [J]. NATURE MEDICINE, 2021, 27 (12) : 2212 - +
  • [5] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
    Julie Westerlin Kjeldsen
    Cathrine Lund Lorentzen
    Evelina Martinenaite
    Eva Ellebaek
    Marco Donia
    Rikke Boedker Holmstroem
    Tobias Wirenfeldt Klausen
    Cecilie Oelvang Madsen
    Shamaila Munir Ahmed
    Stine Emilie Weis-Banke
    Morten Orebo Holmström
    Helle Westergren Hendel
    Eva Ehrnrooth
    Mai-Britt Zocca
    Ayako Wakatsuki Pedersen
    Mads Hald Andersen
    Inge Marie Svane
    [J]. Nature Medicine, 2021, 27 : 2212 - 2223
  • [6] Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
    Julie Westerlin Kjeldsen
    Cathrine Lund Lorentzen
    Evelina Martinenaite
    Eva Ellebaek
    Marco Donia
    Rikke Boedker Holmstroem
    Tobias Wirenfeldt Klausen
    Cecilie Oelvang Madsen
    Shamaila Munir Ahmed
    Stine Emilie Weis-Banke
    Morten Orebo Holmström
    Helle Westergren Hendel
    Eva Ehrnrooth
    Mai-Britt Zocca
    Ayako Wakatsuki Pedersen
    Mads Hald Andersen
    Inge Marie Svane
    [J]. Nature Medicine, 2022, 28 : 871 - 871
  • [7] A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma (vol 27, pg 2212, 2021)
    Kjeldsen, Julie Westerlin
    Lorentzen, Cathrine Lund
    Martinenaite, Evelina
    Ellebaek, Eva
    Donia, Marco
    Holmstroem, Rikke Boedker
    Klausen, Tobias Wirenfeldt
    Madsen, Cecilie Oelvang
    Ahmed, Shamaila Munir
    Weis-Banke, Stine Emilie
    Holmstrom, Morten Orebo
    Hendel, Helle Westergren
    Ehrnrooth, Eva
    Zocca, Mai-Britt
    Pedersen, Ayako Wakatsuki
    Andersen, Mads Hald
    Svane, Inge Marie
    [J]. NATURE MEDICINE, 2022, 28 (04) : 871 - 871
  • [8] Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
    Algazi, Alain P.
    Tsai, Katy K.
    Shoushtari, Alexander N.
    Munhoz, Rodrigo R.
    Eroglu, Zeynep
    Piulats, Josep M.
    Ott, Patrick A.
    Johnson, Douglas B.
    Hwang, Jimmy
    Daud, Adil I.
    Sosman, Jeffrey A.
    Carvajal, Richard D.
    Chmielowski, Bartosz
    Postow, Michael A.
    Weber, Jeffrey S.
    Sullivan, Ryan J.
    [J]. CANCER, 2016, 122 (21) : 3344 - 3353
  • [9] Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma
    Gibney, Geoffrey Thomas
    Weber, Jeffrey S.
    Kudchadkar, Ragini Reiney
    De Conti, Ronald C.
    Tetteh, Leticia
    Eysmans, Cabell
    Yu, Bin
    Martinez, Alberto J.
    Younos, Ibrahim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] CLINICAL OUTCOMES OF METASTATIC MELANOMA PATIENTS WITH LIVER METASTASES TREATED WITH ANTI-PD-1 MONOTHERAPY VERSUS COMBINATION IPILIMUMAB/NIVOLUMAB
    Ma, Vincent
    Griffith, Kent
    Waninger, Jessica
    Daignault-Newton, Stephanie
    Fecher, Leslie
    Lao, Ajjai Alva Christopher
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A143 - A144
12345